Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, investigators will be examining the intraocular pressure lowering effect of brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Toronto
• Collaborator: Dr. Efrem Mandelcorn
• Treatments: Brimonidine Tartrate; Endothelial Growth Factors

Criteria

Inclusion Criteria:

• received ≥1 treatments for age-related macular degeneration (AMD), diabetic macular edema (DME) or macula edema secondary to branch retinal vein occlusion (BRVO)

Exclusion Criteria:

• baseline diagnosis of glaucoma

• baseline IOP during last visit of greater than 21 mmHg

• ongoing use of topical medications (eg. corticosteroids)

• pseudophakic with an anterior chamber intraocular lens

• history of ocular conditions that may impact IOP (eg. pseudoexfoliation)

• previous in-office (eg. laser peripheral iridotomy) and vitreoretinal surgical procedures (eg. pars plana vitrectomy).